Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.71 |
| ▸ | KDR | P35968 | 10/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.51 |
| ▸ | LCK | P06239 | 8/20 | 0.51 |
| ▸ | FYN | P06241 | 8/20 | 0.51 |
| ▸ | YES1 | P07947 | 8/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.51 |
| ▸ | SYK | P43405 | 3/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | FCER2 | P06734 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6391553 | 1.00 | SRC (0.71) | SRCKDRCDK2FGFR1LCK | |
| SCHEMBL6394621 | 0.88 | SYK (0.64) | SRCKDRCDK2FGFR1PDGFRB | |
| SCHEMBL6394625 | 0.88 | SYK (0.64) | SRCKDRCDK2FGFR1PDGFRB | |
| SCHEMBL5181577 | 0.87 | SRC (0.65) | SRCKDRCDK2FGFR1LCK | |
| SCHEMBL5181573 | 0.87 | SRC (0.65) | SRCKDRCDK2FGFR1LCK | |
| SCHEMBL6393552 | 0.86 | SRC (0.59) | SRCKDRCDK2FGFR1FYN | |
| SCHEMBL6393548 | 0.86 | SRC (0.59) | SRCKDRCDK2FGFR1FYN | |
| SCHEMBL6407991 | 0.84 | SRC (1.00) | SRCKDRFGFR1LCKFYN | |
| SCHEMBL6407987 | 0.84 | SRC (1.00) | SRCKDRFGFR1LCKFYN | |
| SCHEMBL6388177 | 0.82 | RET (0.60) | SRCKDRCDK2FGFR1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680335-B2 | FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY | SUGEN, INC. | 2004-01-20 | — | — | US | claimed |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2002-12-05 | — | — | US | claimed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6680335-B2 | FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY | SUGEN, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | SRC 260/4885KDR 1617/4885CDK2 76/4885 |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | PNCK, CAMK4, CAMK1 | SRC 48/4885KDR 728/4885CDK2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.